



Ischemic Stroke and Myocardial Infarction: Potential Therapeutic Targets and Translational Research

Guest Editor:

**Prof. Dr. Macarena
Hernández-Jiménez**

Department of Pharmacology
and Toxicology, Faculty of
Medicine, Complutense
University, Madrid, Spain

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editor

Dear Colleagues,

Despite the implementation of therapies for recanalization, stroke remains the second leading cause of death and the first cause of disability in adults worldwide. Several cerebroprotective drugs are currently in clinical trials but, to date, none of them have demonstrate efficacy in large clinical trials. Therefore, the identification of new targets and the development of novel therapeutic approaches is still necessary to improve the patients' outcomes and quality of life after suffering a stroke. The aim of this Special Issue is to present new therapeutic approaches by taking into account good research practices that guarantee animal wellbeing and provide translational results to support further clinical trials in the stroke field.

Dr. Macarena Hernández-Jiménez
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)